The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

The EU's drug regulator has approved Bavarian Nordic's mpox vaccine for use in adolescents aged 12 to 17 years, the company ...

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

Bavarian Nordic A/S, one of the only companies with a vaccine approved for mpox, has received regulatory approval in Europe ...

The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to ...

The World Health Organization and partners on Friday set up a scheme to help bring mpox vaccines, tests and treatments to the ...

Gavi, the global vaccine group, announced it will purchase 500,000 doses of Bavarian Nordic’s mpox vaccine. This marks Gavi’s ...

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents ...

Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as ...

This represents an important milestone in our efforts to make our vaccine available for all populations and will help improve access for some of the most vulnerable individuals mostly impacted by the ...